Company Filing History:
Years Active: 2021-2023
Title: Innovations of Samuel Evgin
Introduction
Samuel Evgin is a notable inventor based in Ludwigshafen, Germany. He has made significant contributions to the field of diagnostics, holding a total of three patents. His work focuses on methods and devices that enhance the determination of analyte concentrations in bodily fluids.
Latest Patents
One of Samuel Evgin's latest patents is a method and device for determining a concentration of at least one analyte. This method involves generating an excitation voltage signal that includes a poly frequent alternating current (AC) voltage and a direct current (DC) voltage profile. The process includes several steps: signal generation, signal application to measurement electrodes, response measurement, evaluation of AC and DC current responses, and finally, determining the concentration of the analyte based on the responses.
Another significant patent is a method for determining information on equivalent series resistance. This method includes generating an excitation voltage signal, applying it to measurement electrodes, measuring a response signal, and determining an ohmic signal portion from the response. The information on equivalent series resistance is then derived from the ohmic signal portion.
Career Highlights
Samuel Evgin has worked with prominent companies in the diagnostics field, including Roche Diagnostics Operations, Inc. and Roche Diagnostics GmbH. His experience in these organizations has contributed to his expertise and innovative capabilities in developing diagnostic technologies.
Collaborations
Samuel has collaborated with notable coworkers such as Michael Marquant and Melanie Klein. Their teamwork has likely fostered an environment of innovation and creativity in their projects.
Conclusion
Samuel Evgin's contributions to the field of diagnostics through his patents and collaborations highlight his role as an influential inventor. His innovative methods for determining analyte concentrations and equivalent series resistance demonstrate his commitment to advancing medical technology.